fda semaglutide compounding warning november 2025 Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Pharmacy Operating Without Control FDA Drug Recalls and Warnings:

Head-to-head comparison table The gap is not subtle

Jordan Feigenbaum goes through the actual studies behind each scare: the kidney trials, the 2014 IGF-1 and cancer paper that started the panic, the acid-ash bone hypothesis, and the per-meal "cap." Each fear starts from a real mechanism, and each one was run straight to a frightening conclusion the clinical outcomes never supported

Clevers, Tales from the crypt: New insights into intestinal stem cells

One area of particular relevance for women considering retatrutide is its potential interaction with hormonal and reproductive health

PT-141 is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (CHNO, 1025.2 g/mol, CAS 189691-06-3)

Another study, the PIONEER-6 trial, focused on oral semaglutide and its effects on cardiovascular outcomes